11.35
-1(-8.10%)
Currency In USD
| Previous Close | 12.35 |
| Open | 12.35 |
| Day High | 12.43 |
| Day Low | 10.94 |
| 52-Week High | 17.15 |
| 52-Week Low | 6.91 |
| Volume | 1.28M |
| Average Volume | 95,261 |
| Market Cap | 297.94M |
| PE | -2.26 |
| EPS | -5.03 |
| Moving Average 50 Days | 14.38 |
| Moving Average 200 Days | 12.02 |
| Change | -1 |
If you invested $1000 in Benitec Biopharma Inc. (BNTC) 10 years ago, it would be worth $4.15 as of June 28, 2025 at a share price of $11.35. Whereas If you bought $1000 worth of Benitec Biopharma Inc. (BNTC) shares 5 years ago, it would be worth $83.62 as of June 28, 2025 at a share price of $11.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering
GlobeNewswire Inc.
Mar 25, 2025 12:00 PM GMT
HAYWARD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-di
Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
GlobeNewswire Inc.
Mar 19, 2025 11:00 AM GMT
-Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 1- -Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for S
Benitec Biopharma to Participate in Upcoming Conferences in March
GlobeNewswire Inc.
Feb 26, 2025 12:00 PM GMT
HAYWARD, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silenc